Net margin is calculated as Net Income divided by its Revenue. UroGen Pharma's Net Income for the
three
months ended in Mar. 2026 was €-20.4 Mil. UroGen Pharma's Revenue for the
three
months ended in Mar. 2026 was €44.1 Mil. Therefore, UroGen Pharma's net margin for the quarter that ended in Mar. 2026 was -46.26%.
The historical rank and industry rank for UroGen Pharma's Net Margin % or its related term are showing as below:
FRA:UR8'
s Net Margin % Range Over the Past 10 Years
Min: -584144.44 Med: -200.63 Max: -11.07
Current: -94.83
FRA:UR8's Net Margin % is ranked worse than 50.85% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:UR8: -94.83
UroGen Pharma (FRA:UR8) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
UroGen Pharma Net Margin % Related Terms
UroGen Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs OCS, SEPN, AVBP: Net Margin % Comparison
For the Biotechnology subindustry, UroGen Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a Net Margin % of -46.26% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #481 out of 946 companies in the Biotechnology industry, placing it in the top 50.8%.
Is UroGen Pharma's Net Margin % too high?
UroGen Pharma's current Net Margin % is -46.26%. Based on the distribution chart, UroGen Pharma ranks #481 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Net Margin % compare to OCS and SEPN?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #481 out of 946 companies for Net Margin %. This places UroGen Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Net Margin % is -46.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.05, compared to a current price of €29.44 — trading 72.7% above its estimated fair value. The current Net Margin % is -46.26%. UroGen Pharma's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Net Margin % is -46.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €29.44 is trading 72.7% above its estimated GF Value™ of €17.05.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Net Margin %: -46.26%
GF Value™: €17.05 vs. price of €29.44 (72.7% above fair value)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
67GF Score
Get the complete analysis for FRA:UR8
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
